Thank you to Benjamin Burnett, Ph.D. and Stifel Financial Corp. for hosting us for a fireside chat at the 2024 Stifel Healthcare Conference! A replay of the discussion is available here: https://lnkd.in/gE3DwSYm
Jasper Therapeutics
Biotechnology Research
Redwood City, CA 7,202 followers
About us
Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.
- Website
-
http://www.jaspertx.com
External link for Jasper Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, CA
- Type
- Public Company
Locations
-
Primary
Redwood City, CA, US
Employees at Jasper Therapeutics
-
Brent Eberle
Talent Acquisition Leader
-
Svetlana Lucas
Chief Business Officer at Scribe Therapeutics
-
Mark Camarena
Vice President of Information Technology at Jasper Therapeutics
-
Ed Tucker MD MBA
Chief Medical Officer | Advancing New Medicines for Unmet Medical Needs | Mentor | Strategic Advisor
Updates
-
Earlier this morning we announced our financial results for the third quarter of 2024 and provided an overview of recent developments. The full press release is available here: https://lnkd.in/gGQPX2S2
-
Thank you to the American College of Allergy, Asthma and Immunology (ACAAI) for hosting an excellent conference highlighting exciting developments in the field of allergy/immunology. Our #ACAAI24 presentations are available here: https://lnkd.in/gSYnDXYQ
-
The Jasper team is in Boston for the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting and is presenting preclinical briquilimab data. Please stop by the our booth if you're in town for the conference! #ACAAI24
-
Jasper Therapeutics reposted this
With positive results for patients with the chronic skin condition, Jasper Therapeutics' briquilimab is looking to take on Novartis and Genentech's Xolair as well as Sanofi and Regeneron's Dupixent. #pharma #biospace https://hubs.li/Q02Tqm-70
-
This morning we announced positive preliminary data from our SPOTLIGHT study in CIndU. Read the full announcement here: https://lnkd.in/gwe5FtCv
-
Jasper Therapeutics reposted this
#WorldUrticariaDay. Join us live NOW at GA²LEN e.V. UCARE 4 U Instagram channel with two UCARE experts, Prof. Dr. Torsten Zuberbier and Sophia Neisinger, and a special guest, Kristen Willard from Global Allergy & Airways Patient Platform A “All things urticaria” podcast episode will be created from this Instagram Live! https://lnkd.in/dQYx9sXF
-
The Jasper team is proud to recognize #UrticariaDay2024 this October 1st!
-
Jasper Therapeutics reposted this
On Urticaria Day, we remember Professor Marcus Maurer (1966–2024), a remarkable leader in the field of dermatology and allergy. His untimely passing on 7 September 2024 has left a profound impact on the global allergy and immunology community. Professor Maurer's contributions to urticaria research were transformative. As Deputy Director of the Institute of Allergology at Charité - Universitätsmedizin Berlin and Co-Director of Immunology and Allergology at Fraunhofer ITMP, his pioneering work on mast cells, urticaria, and related conditions significantly advanced both scientific understanding and patient care. Through initiatives like GA²LEN, UCARE, and ACARE, he reshaped how urticaria is diagnosed and treated worldwide, providing better outcomes and hope for countless patients. His legacy of leadership, collaboration, and mentorship will continue to inspire future generations. Today, we honour his life’s work and the indelible mark he left on the field of urticaria research. Our thoughts remain with his family, and we hold his memory close. Professor Maurer, your dedication and the „Never give up“ spirit will forever guide us.